Fig. 6From: 4D label-free proteomics analysis of oxygen-induced retinopathy with or without anti-VEGF treatmentIPR analyses of the DEPs. A IPR analyses of the DEPs between the ranibizumab group and the OIR group. B IPR analyses of the DEPs between the OIR group and the normal group. C IPR analyses of the DEPs between the ranibizumab group and the normal groupBack to article page